Apellis Pharmaceuticals, Inc.

APLS

Apellis Pharmaceuticals, Inc.

APLS

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-02-11Shares Purchased (TTM):0Shares Sold (TTM):369,987

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:134,925,349Shares Outstanding:127,682,000Institutional Ownership Pct.:105.67%

Earnings Market Reaction:

Filing Date:2026-05-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Apellis Pharmaceuticals, Inc. (APLS) — SEC Financial Statements & Analysis

Apellis Pharmaceuticals, Inc. (APLS) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	405	466	479	370	358	411	397	360	326	351	452	616
Accounts Receivable Net Current	440	366	346	214	235	265	279	304	268	206	169	111
Inventory Net	131	143	123	121	82	81	121	153	161	146	99	103
Prepaid Expense Current	-	-	32	29	37	18	24	29	43	39	45	34
Prepaid Expense And Other Assets Current	50	38	-	-	-	30	-	-	-	-	-	-
Restricted Cash Current	2	2	1	1	1	1	1	1	1	1	1	1
Other Assets Current	-	-	10	20	13	12	12	12	12	22	31	27
Assets Current	1,028	1,015	991	756	728	789	834	860	811	766	797	893
Assets Noncurrent
Operating Lease Right Of Use Asset	19	18	20	15	15	16	17	16	15	17	15	17
Property Plant And Equipment Net	1	2	2	2	3	3	3	4	4	4	5	5
Inventory Noncurrent	28	35	41	48	61	76	46	23	-	-	-	-
Other Assets Noncurrent	6	6	5	1	1	1	1	1	1	1	1	1
Assets	1,083	1,075	1,059	821	807	885	902	904	832	789	818	916
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	49	57	39	54	55	39	43	38	27	38	18	28
Accrued Liabilities Current	134	166	140	139	116	140	140	123	101	128	117	98
Convertible Debt Current	94	94	94	-	-	0	-	-	-	-	-	-
Operating Lease Liability Current	7	7	7	7	7	7	7	6	6	6	6	6
Deferred Revenue	-	-	-	-	-	-	2	2	4	-	-	-
Liabilities Current	283	324	280	201	178	186	191	169	215	248	186	175
Liabilities Noncurrent
Long Term Line Of Credit	362	362	361	361	360	359	359	364	-	-	-	-
Convertible Debt Noncurrent	-	0	0	94	93	93	93	93	93	93	93	93
Operating Lease Liability Noncurrent	13	12	14	8	9	10	11	11	10	11	11	12
Other Liabilities Noncurrent	9	8	3	2	2	8	10	3	3	2	1	0
Liabilities	668	705	658	665	643	657	665	640	565	594	586	570
Stockholders Equity
Preferred Stock Value	0	0	0	0	-	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	3,412	3,385	3,358	3,329	3,295	3,267	3,239	3,209	3,174	3,036	2,982	2,955
Accumulated Other Comprehensive Income Loss Net Of…	-2	-2	-2	-3	-3	-3	-3	-3	-4	-4	-1	-1
Retained Earnings Accumulated Deficit	-2,994	-3,013	-2,954	-3,170	-3,128	-3,035	-2,999	-2,942	-2,904	-2,837	-2,749	-2,609
Stockholders Equity	415	370	401	156	164	229	237	264	267	195	232	345
Liabilities And Stockholders Equity	1,083	1,075	1,059	821	807	885	902	904	832	789	818	916
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	128	127	127	126	126	124	122	122	121	120	118	118
Shares Outstanding	128	127	127	126	126	124	122	122	121	120	118	118

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-	-	-	-	-	-	-	-	-	-	-	-
2025	-5.89%	-3.11%	8.89%	25.20%	3.00%	9.76%	-5.40%	18.91%	-3.81%	-21.91%	85.57%	86.16%
2024	-10.59%	-12.62%	-9.45%	11.42%	-9.69%	-22.22%	20.85%	16.40%	6.86%	-4.02%	-27.63%	-30.62%
2023	-	-	-	58.33%	69.98%	80.19%	-3.01%	15.67%	27.86%	-20.13%	-31.46%	-40.43%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	3.63	3.14	3.54	3.77	4.08	4.25	4.36	5.08	3.77	3.10	4.29	5.11
Quick Ratio	2.99	2.58	2.99	3.02	3.41	3.72	3.60	4.01	2.82	2.35	3.52	4.32
Working Capital	744.57M	691.24M	711.15M	554.95M	549.34M	603.45M	642.64M	690.81M	596.14M	518.74M	611.14M	717.85M
Leverage & Debt
Debt to Equity	1.61	1.90	1.64	4.26	3.92	2.87	2.80	2.42	2.12	3.05	2.52	1.65
Debt Ratio	0.62	0.66	0.62	0.81	0.80	0.74	0.74	0.71	0.68	0.75	0.72	0.62
Efficiency & Turnover
Asset Turnover TTM	1.17	1.02	1.04	0.87	0.95	0.93	0.83	0.69	0.58	0.51	0.32	0.19
Days Sales Outstanding TTM	111.54	114.75	112.14	125.41	118.34	110.10	114.38	120.55	104.24	98.55	118.61	117.13
Receivables Turnover TTM	3.27	3.18	3.25	2.91	3.08	3.32	3.19	3.03	3.50	3.70	3.08	3.12
Per Share Metrics
Diluted EPS TTM	1.01	0.17	0.35	-1.81	-1.78	-1.60	-2.01	-2.69	-3.39	-4.45	-5.04	-5.51
Free Cash Flow Per Share TTM	0.29	0.36	0.62	0.03	-0.07	-0.71	-1.65	-3.30	-4.48	-5.02	-5.31	-5.23
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	14.95%	5.52%	7.91%	-25.19%	-24.00%	-21.11%	-31.23%	-49.80%	-77.11%	-130.39%	-218.65%	-331.93%
Net Profit Margin TTM	12.06%	2.23%	4.43%	-30.24%	-28.83%	-25.32%	-34.97%	-52.94%	-79.62%	-133.29%	-222.09%	-356.07%
Growth Metrics
Net Revenue Growth (1Y)	42.46%	28.46%	42.11%	20.02%	48.04%	97.02%	162.10%	240.74%	394.93%	425.83%	141.38%	90.94%
Net Income Growth (1Y)	-159.58%	-111.31%	-117.99%	-31.46%	-46.39%	-62.57%	-58.73%	-49.34%	-39.61%	-18.94%	-4.43%	2.92%
EPS Growth (1Y)	-158.54%	-111.11%	-117.68%	-32.61%	-47.46%	-64.15%	-60.04%	-51.21%	-44.08%	-27.52%	-13.30%	-8.02%
Calculated Values
Free Cash Flow TTM	37.46M	45.01M	78.63M	4.41M	-8.41M	-88.27M	-205.58M	-408.81M	-550.91M	-595.51M	-639.13M	-624.61M
Net Debt	-312.98M	-374.10M	-387.02M	-277.97M	-266.41M	-319.27M	-304.97M	-268.24M	-233.92M	-259.27M	-360.54M	-524.46M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-11Sale

Owner: Delong, Mark Jeffrey

Title: Chief Business & Strat Officer

Shares: 368

Price/Share: $22.15

Value: $8,151.20

Shares Owned: 114,591

Relationship: Officer

Ownership: Direct

2026-01-22Sale

Owner: Deschatelets, Pascal

Title: Chief Scientific Officer

Shares: 5,928

Price/Share: $21.77

Value: $129,052.56

Shares Owned: 1,151,382

Relationship: Officer

Ownership: Direct

2026-01-22Sale

Owner: Baumal, Caroline

Title: Chief Medical Officer

Shares: 2,797

Price/Share: $21.77

Value: $60,890.69

Shares Owned: 86,527

Relationship: Officer

Ownership: Direct

2026-01-22Sale

Owner: Watson, David O.

Title: General Counsel

Shares: 7,832

Price/Share: $21.77

Value: $170,502.64

Shares Owned: 88,531

Relationship: Officer

Ownership: Direct

2026-01-22Sale

Owner: Delong, Mark Jeffrey

Title: Chief Business & Strat Officer

Shares: 3,371

Price/Share: $21.77

Value: $73,386.67

Shares Owned: 78,353

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-11	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	368	22.15	$8,151.20	114,591	4
2026-01-22	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	5,928	21.77	$129,052.56	1,151,382	4
2026-01-22	Baumal, Caroline	Officer	Chief Medical Officer	Direct	Sale	2,797	21.77	$60,890.69	86,527	4
2026-01-22	Watson, David O.	Officer	General Counsel	Direct	Sale	7,832	21.77	$170,502.64	88,531	4
2026-01-22	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	3,371	21.77	$73,386.67	78,353	4
2026-01-22	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	10,287	21.77	$223,947.99	93,901	4
2026-01-22	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	2,064	21.77	$44,933.28	49,805	4
2026-01-22	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	7,725	21.77	$168,173.25	71,118	4
2026-01-22	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	27,192	21.77	$591,969.84	286,045	4
2026-01-20	Baumal, Caroline	Officer	Chief Medical Officer	Direct	Sale	1,882	19.79	$37,244.78	89,324	4
2026-01-20	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	726	19.79	$14,367.54	51,869	4
2026-01-20	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	2,203	19.79	$43,597.37	78,843	4
2026-01-20	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	1,334	19.79	$26,399.86	81,724	4
2026-01-20	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	8,182	19.79	$161,921.78	313,237	4
2026-01-20	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	2,892	19.79	$57,232.68	104,188	4
2026-01-20	Watson, David O.	Officer	General Counsel	Direct	Sale	2,475	19.79	$48,980.25	96,363	4
2026-01-20	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	909	19.79	$17,989.11	1,157,310	4
2026-01-13	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	2,277	22.19	$50,526.63	1,158,219	4
2026-01-13	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	2,618	22.19	$58,093.42	81,046	4
2026-01-13	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	10,186	22.19	$226,027.34	321,419	4
2026-01-13	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	1,780	22.19	$39,498.20	83,058	4
2026-01-13	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	3,856	22.19	$85,564.64	107,080	4
2026-01-13	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	873	22.19	$19,371.87	52,595	4
2026-01-13	Watson, David O.	Officer	General Counsel	Direct	Sale	5,780	22.19	$128,258.20	98,838	4
2026-01-05	Baumal, Caroline	Officer	Chief Medical Officer	Direct	Sale	3,020	25.53	$77,100.60	91,206	4
2025-12-16	Watson, David O.	Officer	General Counsel	Direct	Sale	5,000	24.49	$122,450.00	103,730	4
2025-11-17	Watson, David O.	Officer	General Counsel	Direct	Sale	5,000	20.06	$100,300.00	108,730	4
2025-10-21	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	10,000	28.03	$280,300.00	110,936	4
2025-10-16	Watson, David O.	Officer	General Counsel	Direct	Sale	5,000	25.22	$126,100.00	113,730	4
2025-10-10	Dunlop, A. Sinclair	Director	-	Indirect	Sale	31,092	23.72	$737,502.24	3,837	4
2025-09-30	Dunlop, A. Sinclair	Director	-	Indirect	Sale	31,092	22.58	$702,057.36	33,979	4
2025-09-19	Dunlop, A. Sinclair	Director	-	Indirect	Sale	31,092	22.95	$713,561.40	68,908	4
2025-09-16	Watson, David O.	Officer	General Counsel	Direct	Sale	5,000	24.34	$121,700.00	118,730	4
2025-09-15	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	189	24.19	$4,571.91	53,468	4
2025-09-10	Watson, David O.	Officer	General Counsel	Indirect	Sale	20,000	26.17	$523,400.00	50,136	4
2025-09-08	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	32,729	27.86	$911,829.94	110,936	4
2025-09-02	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	548	28.08	$15,387.84	53,657	4
2025-08-28	Francois, Cedric	Director,Officer	Chief Executive Officer	Indirect	Sale	49,963	28.39	$1,418,449.57	307,946	4
2025-08-18	Watson, David O.	Officer	General Counsel	Direct	Sale	5,000	27.80	$139,000.00	123,730	4
2025-07-17	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	19,725	20.21	$398,642.25	331,605	4
2025-07-16	Watson, David O.	Officer	General Counsel	Direct	Sale	5,000	19.55	$97,750.00	128,730	4
2025-07-15	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	1,900	20.09	$38,171.00	342,333	4
2025-06-16	Watson, David O.	Officer	General Counsel	Direct	Sale	5,000	18.77	$93,850.00	133,730	4
2025-03-17	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	183	24.82	$4,542.06	47,955	4
2025-03-05	Watson, David O.	Officer	General Counsel	Direct	Sale	5,569	25.10	$139,781.90	138,730	4
2025-02-11	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	363	28.54	$10,360.02	83,945	4
2025-01-29	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	365	29.52	$10,774.80	84,308	4
2025-01-29	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	825	29.52	$24,354.00	83,664	4
2025-01-29	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	546	29.52	$16,117.92	128,665	4
2025-01-29	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	278	29.52	$8,206.56	55,312	4
2025-01-29	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	2,824	29.52	$83,364.48	415,695	4
2025-01-29	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	695	29.52	$20,516.40	84,050	4
2025-01-29	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	364	29.52	$10,745.28	70,251	4
2025-01-29	Watson, David O.	Officer	General Counsel	Direct	Sale	695	29.52	$20,516.40	144,299	4
2025-01-29	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	826	29.52	$24,383.52	1,147,716	4
2025-01-22	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	1,291	30.43	$39,285.13	55,590	4
2025-01-22	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	1,751	30.43	$53,282.93	70,615	4
2025-01-22	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	1,396	30.43	$42,480.28	84,673	4
2025-01-22	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	3,948	30.43	$120,137.64	1,148,542	4
2025-01-22	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	13,551	30.43	$412,356.93	418,519	4
2025-01-22	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	3,088	30.43	$93,967.84	129,211	4
2025-01-22	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	1,096	30.43	$33,351.28	48,138	4
2025-01-22	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	3,323	30.43	$101,118.89	84,745	4
2025-01-22	Watson, David O.	Officer	General Counsel	Direct	Sale	3,323	30.43	$101,118.89	144,994	4
2025-01-22	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	3,948	30.43	$120,137.64	84,489	4
2025-01-17	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	750	29.96	$22,470.00	1,137,445	4
2025-01-17	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	715	29.96	$21,421.40	36,643	4
2025-01-17	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	1,730	29.96	$51,830.80	86,370	4
2025-01-17	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	2,145	29.96	$64,264.20	52,011	4
2025-01-17	Watson, David O.	Officer	General Counsel	Direct	Sale	2,201	29.96	$65,941.96	105,555	4
2025-01-17	Baumal, Caroline	Officer	Chief Medical Officer	Direct	Sale	1,853	29.96	$55,515.88	53,707	4
2025-01-17	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	2,201	29.96	$65,941.96	88,068	4
2025-01-17	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	1,235	29.96	$37,000.60	57,561	4
2025-01-17	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	1,241	29.96	$37,180.36	43,858	4
2025-01-17	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	6,007	29.96	$179,969.72	301,408	4
2025-01-13	Watson, David O.	Officer	General Counsel	Direct	Sale	4,965	28.70	$142,495.50	107,756	4
2025-01-13	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	783	28.70	$22,472.10	37,358	4
2025-01-13	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	2,288	28.70	$65,665.60	1,138,195	4
2025-01-13	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	2,632	28.70	$75,538.40	54,156	4
2025-01-13	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	2,170	28.70	$62,279.00	88,100	4
2025-01-13	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	1,599	28.70	$45,891.30	45,099	4
2025-01-13	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	6,247	28.70	$179,288.90	307,415	4
2025-01-13	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	2,685	28.70	$77,059.50	90,269	4
2025-01-13	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	1,599	28.70	$45,891.30	58,796	4
2025-01-13	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	264	28.70	$7,576.80	56,881	4
2025-01-06	Baumal, Caroline	Officer	Chief Medical Officer	Direct	Sale	2,816	33.81	$95,208.96	55,560	4
2024-12-23	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	63	33.09	$2,084.67	57,145	4
2024-12-11	Watson, David O.	Officer	General Counsel	Direct	Sale	5,000	34.24	$171,200.00	112,721	4
2024-09-16	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	192	36.21	$6,952.32	38,141	4
2024-09-16	Dunlop, A. Sinclair	Director	-	Indirect	Sale	37,000	36.44	$1,348,280.00	100,000	4
2024-09-03	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	550	39.49	$21,719.50	38,333	4
2024-06-21	Dunlop, A. Sinclair	Director	-	Indirect	Sale	37,000	39.42	$1,458,540.00	136,998	4
2024-05-08	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	78,907	43.01	$3,393,790.07	1,115,983	4
2024-04-08	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	69,107	54.52	$3,767,713.64	1,115,983	4
2024-04-01	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	4,000	58.66	$234,640.00	93,338	4
2024-03-19	Dunlop, A. Sinclair	Director	-	Indirect	Sale	18,681	57.18	$1,068,179.58	173,998	4
2024-03-18	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	9,913	56.90	$564,049.70	54,693	4
2024-03-15	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	184	56.46	$10,388.64	38,883	4
2024-03-13	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	11,220	57.72	$647,618.40	56,287	4
2024-03-08	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	69,107	62.64	$4,328,862.48	1,115,983	4
2024-03-01	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	250,000	64.01	$16,002,500.00	313,662	4
2024-03-01	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	6,000	63.40	$380,400.00	93,338	4
2024-02-12	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	3,962	67.77	$268,504.74	313,662	4
2024-02-12	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	1,148	67.77	$77,799.96	1,115,983	4
2024-02-12	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	1,148	67.77	$77,799.96	92,453	4
2024-02-12	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	1,431	67.77	$96,978.87	93,338	4
2024-02-12	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	597	67.77	$40,458.69	64,606	4
2024-02-12	Watson, David O.	Officer	General Counsel	Direct	Sale	781	67.77	$52,928.37	103,390	4
2024-01-30	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	883	65.53	$57,862.99	46,387	4
2024-01-30	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	971	65.53	$63,629.63	57,208	4
2024-01-29	Watson, David O.	Officer	General Counsel	Direct	Sale	906	64.14	$58,110.84	104,171	4
2024-01-29	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	906	64.14	$58,110.84	94,769	4
2024-01-29	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	874	64.14	$56,058.36	1,117,131	4
2024-01-29	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	835	64.14	$53,556.90	67,507	4
2024-01-29	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	367	64.14	$23,539.38	65,203	4
2024-01-29	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	906	64.14	$58,110.84	93,601	4
2024-01-29	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	2,843	64.14	$182,350.02	317,624	4
2024-01-23	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	4,286	63.69	$272,975.34	47,637	4
2024-01-23	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	7,378	63.69	$469,904.82	58,458	4
2024-01-22	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	13,431	65.00	$873,015.00	320,467	4
2024-01-22	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	1,738	65.00	$112,970.00	51,923	4
2024-01-22	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	3,913	65.00	$254,345.00	1,118,005	4
2024-01-22	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	1,061	65.00	$68,965.00	39,067	4
2024-01-22	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	2,593	65.00	$168,545.00	68,342	4
2024-01-22	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	1,384	65.00	$89,960.00	65,570	4
2024-01-22	Watson, David O.	Officer	General Counsel	Direct	Sale	4,184	65.00	$271,960.00	105,077	4
2024-01-22	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	3,551	65.00	$230,815.00	95,675	4
2024-01-22	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	3,413	65.00	$221,845.00	94,507	4
2024-01-22	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	1,607	65.00	$104,455.00	65,836	4
2024-01-17	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	3,276	65.58	$214,840.08	53,661	4
2024-01-17	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	5,207	65.58	$341,475.06	67,443	4
2024-01-16	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	2,235	66.81	$149,320.35	97,920	4
2024-01-16	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	2,235	66.81	$149,320.35	99,226	4
2024-01-16	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	1,632	66.81	$109,033.92	1,121,918	4
2024-01-16	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	864	66.81	$57,723.84	40,128	4
2024-01-16	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	1,857	66.81	$124,066.17	70,935	4
2024-01-16	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	1,632	66.81	$109,033.92	56,937	4
2024-01-16	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	1,631	66.81	$108,967.11	66,954	4
2024-01-16	Watson, David O.	Officer	General Counsel	Direct	Sale	4,240	66.81	$283,274.40	109,261	4
2024-01-16	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	7,851	66.81	$524,525.31	333,898	4
2024-01-16	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	438	66.81	$29,262.78	72,650	4
2024-01-04	Baumal, Caroline	Officer	Chief Medical Officer	Direct	Sale	2,751	60.05	$165,197.55	32,931	4
2023-12-27	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	235	60.23	$14,154.05	53,580	4
2023-12-19	Watson, David O.	Officer	General Counsel	Direct	Sale	3,905	57.19	$223,326.95	89,753	4
2023-12-01	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	110,000	60.90	$6,699,000.00	76,407	4
2023-12-01	Scheibler, Lukas	Officer	Chief Research Officer	Direct	Sale	10,000	60.00	$600,000.00	68,299	4
2023-12-01	Dunlop, A. Sinclair	Director	-	Indirect	Sale	24,000	61.14	$1,467,360.00	192,679	4
2023-11-30	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	14,158	54.76	$775,292.08	77,713	4
2023-11-21	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	5,000	48.80	$244,000.00	269,655	4
2023-11-17	Dunlop, A. Sinclair	Director	-	Direct	Sale	8,894	49.99	$444,611.06	122,403	4
2023-11-17	Machiels, Alec	Director	-	Direct	Sale	1,250	47.74	$59,675.00	367,420	4
2023-11-08	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	12,000	47.27	$567,240.00	1,071,807	4
2023-10-23	Delong, Mark Jeffrey	Officer	Chief Business & Strat Officer	Direct	Sale	131	46.04	$6,031.24	51,622	4
2023-10-23	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	132	46.04	$6,077.28	32,680	4
2023-10-17	Machiels, Alec	Director	-	Direct	Sale	1,250	48.50	$60,625.00	367,420	4
2023-10-17	Dunlop, A. Sinclair	Director	-	Indirect	Sale	24,000	49.00	$1,176,000.00	216,679	4
2023-10-09	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	12,000	40.38	$484,560.00	1,066,313	4
2023-09-18	Nicholson, Nur	Officer	Chief Technical Officer	Direct	Sale	20,350	44.18	$899,063.00	53,284	4
2023-09-18	Machiels, Alec	Director	-	Direct	Sale	1,250	45.00	$56,250.00	367,420	4
2023-09-15	Machiels, Alec	Director	-	Direct	Sale	1,250	45.34	$56,675.00	367,420	4
2023-09-08	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	12,000	42.87	$514,440.00	1,059,813	4
2023-09-06	Scheibler, Lukas	Officer	Chief Research Officer	Direct	Sale	1,756	43.01	$75,525.56	68,299	4
2023-09-01	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	150,000	42.07	$6,310,500.00	424,655	4
2023-08-31	Chopas, James George	Officer	VP/Chief Accounting Officer	Direct	Sale	551	41.23	$22,717.73	30,312	4
2023-08-08	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	12,000	23.66	$283,920.00	1,053,313	4
2023-07-17	Machiels, Alec	Director	-	Direct	Sale	1,250	64.79	$80,987.50	267,641	4
2023-07-10	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	12,000	84.55	$1,014,600.00	1,046,813	4
2023-07-03	Watson, David O.	Officer	General Counsel	Direct	Sale	8,510	89.98	$765,729.80	85,753	4
2023-07-03	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	6,779	90.31	$612,211.49	77,713	4
2023-06-20	Machiels, Alec	Director	-	Direct	Sale	1,250	88.41	$110,512.50	267,641	4
2023-06-08	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	12,000	91.35	$1,096,200.00	1,040,313	4
2023-06-05	Sullivan, Timothy Eugene	Officer	Chief Financial Officer	Direct	Sale	69,779	89.14	$6,220,100.06	77,713	4
2023-06-01	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	5,000	86.00	$430,000.00	41,504	4
2023-05-17	Machiels, Alec	Director	-	Direct	Sale	1,250	88.66	$110,825.00	267,641	4
2023-05-16	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	85.44	$2,563,200.00	274,655	4
2023-05-08	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	12,000	92.39	$1,108,680.00	1,033,813	4
2023-05-03	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	5,000	82.71	$413,550.00	75,995	4
2023-04-18	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	82.02	$2,460,600.00	637,601	4
2023-04-17	Machiels, Alec	Director	-	Direct	Sale	1,250	81.05	$101,312.50	267,641	4
2023-04-10	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	12,000	78.21	$938,520.00	1,027,313	4
2023-04-03	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	5,000	75.00	$375,000.00	41,430	4
2023-04-03	Dunlop, A. Sinclair	Director	-	Direct	Sale	500	74.05	$37,025.00	131,297	4
2023-04-03	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	5,000	74.05	$370,250.00	75,995	4
2023-03-21	Francois, Cedric	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	62.74	$1,882,200.00	1,144,591	4
2023-03-17	Machiels, Alec	Director	-	Direct	Sale	1,250	64.03	$80,037.50	267,641	4
2023-03-08	Deschatelets, Pascal	Officer	Chief Scientific Officer	Direct	Sale	12,000	63.79	$765,480.00	1,020,813	4
2023-03-03	Townsend, Adam J.	Officer	Chief Commercial Officer	Direct	Sale	5,000	63.84	$319,200.00	75,995	4
2023-03-01	Dunlop, A. Sinclair	Director	-	Direct	Sale	500	65.33	$32,665.00	131,797	4
2023-02-23	Lewis, Karen	Officer	Chief People Officer	Direct	Sale	1,104	68.76	$75,911.04	41,430	4
2023-02-23	Eisele, Jeffrey	Officer	Chief Development Officer	Direct	Sale	1,646	68.76	$113,178.96	53,883	4
2023-02-17	Machiels, Alec	Director	-	Direct	Sale	1,250	52.38	$65,475.00	267,641	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

105.67%

Inst. Shares: 134,925,349

Shares Outstanding: 127,682,000

2025-12-31

99.10%

Inst. Shares: 125,015,716

Shares Outstanding: 126,145,000

2025-09-30

95.81%

Inst. Shares: 121,121,297

Shares Outstanding: 126,424,000

2025-06-30

103.55%

Inst. Shares: 130,500,254

Shares Outstanding: 126,024,000

2025-03-31

97.77%

Inst. Shares: 122,651,376

Shares Outstanding: 125,453,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	134,925,349	127,682,000	105.67%
2025-12-31	125,015,716	126,145,000	99.10%
2025-09-30	121,121,297	126,424,000	95.81%
2025-06-30	130,500,254	126,024,000	103.55%
2025-03-31	122,651,376	125,453,000	97.77%
2024-12-31	125,384,817	123,905,000	101.19%
2024-09-30	112,496,098	124,234,000	90.55%
2024-06-30	108,794,431	123,904,000	87.81%
2024-03-31	104,119,305	122,956,835	84.68%
2023-12-31	102,284,994	118,678,000	86.19%
2023-09-30	101,057,775	120,292,000	84.01%
2023-06-30	87,543,857	119,316,000	73.37%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Apellis Pharmaceuticals, Inc. (APLS) — SEC Financial Statements & Analysis

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.